abstract |
The present invention discloses an edaravone pharmaceutical composition containing edaravone or a salt thereof and mannitol, and its use as a sublingual preparation thereof. Sublingual preparations can avoid the first-pass effect of the liver, and have advantages such as good stability of the sample, easy transportation, and convenient use. [Selection diagram] None |